Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Maneesh Paul Satyaseela, M.Sc., Ph. D., FIDSA (he/him/his)

CEO
Microvioma
Bengaluru, Karnataka, India

Dr. Maneesh Paul. S, M. Sc., Ph. D., FIDSA
Program Director and Lead Co-Inventor of Enmetazobactam,
Drug Discovery & Development, Orchid Pharma, Chennai, India

Dr. Maneesh Paul-Satyaseela led the R&D of Enmetazobactam at Orchid Pharma, India which is the first Indian anti-infective NCE to have been approved by the USFDA, and EMA, UKMHRA for Marketing 2024 (by out-licensing to Allecra Therapeutics GmbH) and now by DCGI in India.

He is a clinical microbiologist who pursued basic and applied research discovering novel anti-infectives and characterizing several microbial genes and proteins. He led the anti-infectives discovery research group as Biologist at Orchid Pharma, and co-invented several pre-clinical candidates in anti-bacterial and anti-fungal space

Dr. Maneesh has translated scientific accomplishments and leadership through patents and publications. He received his Master’s, and Doctoral degrees in medical microbiology from India (MAHE & Gulbarga Univ). As a postdoctoral fellow, he got trained in infectious diseases, specifically in molecular mechanisms of microbial pathogenesis at Johns Hopkins School of Medicine, USA, and at Umeå University, Sweden. He was the ORISE Fellow at the Center for Biologics Evaluation and Research, USFDA, MD, USA working on reverse vaccinology. He was the member of AMR Committee of Infectious Diseases Society of America; he is now (2024) conferred with the prestigious FIDSA qualification. He is currently the member of the Strategic Advisory Committee of UK government’s AMR initiative PACE (Pathway for Antimicrobial Clinical Efficacy), and on several AMR initiatives in India.

Dr. Maneesh has founded the social initiative AMRACE (AMR Action Collaborative Engagement) to engage stakeholders from all verticals of One-Health towards Community Stewardship to Preserve the existing Antibiotics. In 2022 he also founded Microvioma (P) Ltd, India, a research-based organization founded on verified science to participate in the fight against AMR & WHO’s One Health mission by providing microbiology-based solutions & products.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):